Ketorolac Tromethamine Articles

Allergan reports strong 4th-qtr results

13 February 2006

Allergan wins Acular patent case

5 January 2004

US FDA OKays Allergan's Acular LS

9 June 2003

Market News

30 October 1997

First Approval Of AHP's Duract

17 July 1997

First-Quarter Sales At Roche Up 18%

21 April 1997

Wall Street Disappointment With Biogen Hits Teva

26 March 1997

New Indication For Acular

13 January 1997

Recordati Sales Boost From Rx Abroad, Italian OTCs

7 August 1995

Disease ManagementThe Way Forward

15 May 1995

European STOCK COMMENT

10 April 1995

Toradol Removal From Hospital Setting

3 April 1995

SYNTEX SUCCUMBS TO $5.3 BILL OFFER FROM ROCHE

9 May 1994

KETOROLAC ADVERSE REACTIONS DECLINE

18 April 1994

MORE NEWS ON TORADOL IN EUROPE

4 April 1994

MIGRAINE MARKET SET TO BLOSSOM

21 February 1994

SYNTEX CHIEF SPEAKS ON PRODUCT PROSPECTS

24 January 1994

FRANCE SUSPENDS KETOROLAC LICENSE

10 January 1994

SYNTEX EXPECTS PATENT EXPIRY EFFECTS

13 December 1993

CLARIFYING TORADOL POSITION IN GERMANY

22 November 1993

TORADOL LABELLING

8 November 1993

EC CPMP REPORT ON SYNTEX' KETOROLAC

28 June 1993

SYNTEX' KETOROLAC WITHDRAWN IN GERMANY

21 June 1993

SYNTEX PROFITS HIT BY RESTRUCTURING

7 June 1993

SPENDING CONTROL AT SYNTEX IN Q2

8 March 1993

SYNTEX SHIFTS PLANT TO PUERTO RICO

1 March 1993

FISONS FUTURE STRATEGY DIRECTION

22 February 1993

FISONS AND ALLERGAN LINK-UP

8 February 1993

ABPI CODE OF PRACTICE LATEST REPORT

21 December 1992

SYNTEX POSTS FIRST QTR LOSSES

7 December 1992

TORADOL LINKED TO SERIOUS REACTIONS

9 November 1992

SYNTEX INVESTMENT FOR FUTURE GROWTH

29 June 1992

COMPANIES DO MORE LICENSING DEALS

4 May 1992

STOCK MARKET COMMENTARY: NEW YORK

20 April 1992

SYNTEX POSTS STRONG 2ND QTR

9 March 1992

SYNTEX "A COMPANY ON THE MOVE"

20 January 1992

SYNTEX' ORAL TORADOL APPROVED IN USA

13 January 1992

STOCK MARKET COMMENTARY: NEW YORK

6 January 1992

Showing 1-38 of 38 articles

Go to beginningPrevious
  • 1
NextGo to end